

Sub. H. B. No. 96  
As Passed by the Senate  
MHACD32

\_\_\_\_\_ moved to amend as follows:

After line 156908, insert:

**"Section 751.40.** (A) The Ibogaine Treatment Study Committee is established to study and evaluate the use of ibogaine for the care and treatment of individuals with substance use disorders and veterans with post-traumatic stress disorder, depression, and mild traumatic brain injuries. In conducting its study and evaluation, the committee shall consider the following topics:

(1) The needs of individuals with substance use disorders;

(2) The needs of veterans with post-traumatic stress disorder, depression, and mild traumatic brain injuries;

(3) The efficacy of using ibogaine for the care and treatment of the individuals specified in divisions (A) (1) and (2) of this section, including a review of available scientific literature;

(4) State and federal law regarding ibogaine;

(5) Any other topics the committee considers relevant.

(B) The committee consists of the following six members: 18

(1) Four members of the General Assembly, two appointed by 19  
the Speaker of the House of Representatives and two appointed by 20  
the Senate President; 21

(2) The Director of Behavioral Health or the Director's 22  
designee; 23

(3) The Director of Veterans Services or the Director's 24  
designee. 25

The members shall be appointed not later than thirty days 26  
after the effective date of this section. Vacancies, including 27  
any vacancy due to the expiration of a member of the General 28  
Assembly's term of office, shall be filled not later than thirty 29  
days after the vacancy occurs in the same manner as the original 30  
appointment. The members shall select a chairperson from among 31  
the committee's membership and shall meet as necessary to 32  
satisfy the requirements of this section. 33

(C) Not later than December 31, 2027, the committee shall 34  
prepare and submit to the General Assembly a report of its 35  
recommendations for legislation addressing use of ibogaine for 36  
the care and treatment of individuals with substance use 37  
disorders and veterans with post-traumatic stress disorder, 38  
depression, and mild traumatic brain injuries. The report shall 39  
be submitted in accordance with section 101.68 of the Revised 40  
Code. The Ohio Department of Behavioral Health shall provide to 41  
the committee the administrative support necessary to execute 42  
its duties. 43

(D) The committee ceases to exist on the submission of the 44  
report described in division (C) of this section." 45

The motion was \_\_\_\_\_ agreed to.

**SYNOPSIS**

46

**Ibogaine Treatment Study Committee**

47

**Section 751.40**

48

Restores provisions added by the House and removed by the  
Senate that do the following:

49

50

-Establish the Ibogaine Treatment Study Committee to  
evaluate the use of ibogaine for treating individuals with  
substance use disorders and veterans with post-traumatic stress  
disorder, depression, and mild traumatic brain injuries.

51

52

53

54

-Require the Department of Behavioral Health to provide  
administrative support to the committee.

55

56

-Require the committee to submit a report with  
recommendations for legislation addressing the use of ibogaine  
to the General Assembly by December 31, 2027, after which the  
committee ceases to exist.

57

58

59

60